Proteomics labs worldwide can now access SomaLogic’s industry-leading 7,000-plex SomaScan® Assay with the Certified Site program
BOULDER, Colo., Dec. 07, 2022 (GLOBE NEWSWIRE) — SomaLogic, Inc., a leader in proteomics technology, announced today the full-scale global launch of the SomaLogic™ Certified Site program, which will allow institutions around the world to run the 7,000-plex SomaScan® Assay in their own labs. By becoming a SomaLogic Certified Site, labs can run assays on SomaLogic’s SomaScan® Platform—the largest commercially available proteomics platform—and accelerate their own research and generate revenue as a service provider. SomaLogic Certified Sites receive support services, on-site training and equipment servicing.
Related news for (SLGC)
- SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting
- Madryn Asset Management Addresses SomaLogic’s Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools
- Proxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools
- SomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting “FOR” Pending Merger with Standard BioTools
- Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures